Activation of RAS family members confers resistance to ROS1 targeting drugs. (Q34463388)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Activation of RAS family members confers resistance to ROS1 targeting drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author

Margherita Pergolizzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Robert C Doebele

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Marileila Varella-Garcia

object named as

Marileila Varella-Garcia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Dara L Aisner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Marilisa Cargnelutti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Simona Corso

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Laurence Mévellec

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Paolo M Comoglio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Jorge Vialard

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

English

0 references

publication date

1 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

5182-5194

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

The democratization of the oncogene

1 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Dragging ras back in the ring

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Molecular pathways: ROS1 fusion proteins in cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

RET, ROS1 and ALK fusions in lung cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

ROS1 rearrangements define a unique molecular class of lung cancers

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

6 July 2018

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

The protein tyrosine kinase family of the human genome

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4467141

Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25691052

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.18632/ONCOTARGET.3311

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

PubMed publication ID

25691052

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25691052%20AND%20SRC:MED&resulttype=core&format=json